NCT03822377View on ClinicalTrials.gov

Ticagrelor Administered as Standard Tablet or Orodispersible Formulation

PHASE3CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

June 27, 2019

Primary Completion Date

August 31, 2020

Study Completion Date

August 31, 2020

Conditions
ST Elevation Myocardial InfarctionNSTEMI - Non-ST Segment Elevation MI
Interventions
DRUG

Ticagrelor orodispersible tablets

Ticagrelor loading dose (180 mg) given as two orodispersible tablets (each of 90 mg), to be dispersed in saliva.

DRUG

Ticagrelor standard tablets

Ticagrelor loading dose (180 mg) given as two standard coated tablets (each of 90 mg) to be swallowed with water.

Trial Locations (1)

07100

Cardiologia Clinica e Interventistica - AOU Sassari, Sassari

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Azienda Ospedaliero Universitaria di Sassari

OTHER